

## Regimen Reference Order – MYEL – carfilzomib + dexamethasone

ARIA: MYEL – [carfilzomib + dexamethasone]

Planned Course: Until disease progression or unacceptable toxicity (1 cycle = 28 days)

Indication for Use: Multiple Myeloma

CVAD: At Provider's Discretion

### Proceed with treatment if:

#### Day 1 and 15 only

- ANC equal to or greater than  $0.5 \times 10^9/L$  AND Platelets equal to or greater than  $30 \times 10^9/L$ 
  - ❖ Contact Hematologist if parameters not met

## SEQUENCE OF MEDICATION ADMINISTRATION

### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Instruct patient to start vigorous oral pre-hydration of 6 to 8 cups of liquid per day starting at least 48 hours before Cycle 1 only		
allopurinol*	300 mg	Orally once daily for 10 days to begin 3 days prior to Cycle 1 and at provider's discretion for subsequent cycles *Only patients at risk of tumor lysis syndrome will be prescribed allopurinol

### Treatment Regimen – MYEL – carfilzomib + dexamethasone

Establish primary solution 500 mL of: normal saline		
Drug	Dose	CCMB Administration Guideline
<b>Cycle 1</b>		
dexamethasone	40 mg	Orally once daily on <b>Days 1, 8, 15 and 22</b> <b>(Self-administered at home)</b> <i>*Alert: On days of carfilzomib administration, dexamethasone should be taken between <u>30 minutes to 4 hours</u> prior to carfilzomib</i>
normal saline	500 mL	IV over 1 hour prior to carfilzomib (Pre-hydration) on <b>Days 1, 8 and 15</b>
carfilzomib	20 mg/m <sup>2</sup>	IV in D5W 100 mL over 30 minutes on <b>Day 1</b>
	70 mg/m <sup>2</sup>	IV in D5W 100 mL over 30 minutes on <b>Days 8 and 15</b>
normal saline	500 mL	Infused over the 1 hour observation period (Post-hydration) on <b>Days 1, 8 and 15</b>
<b>Cycle 2 onwards</b>		
dexamethasone	40 mg	Orally once daily on <b>Days 1, 8, 15 and 22</b>

		<b>(Self-administered at home)</b> <i>*Alert:</i> On days of carfilzomib administration, dexamethasone should be taken between <u>30 minutes to 4 hours</u> prior to carfilzomib
carfilzomib	70 mg/m <sup>2</sup>	IV in D5W 100 mL over 30 minutes on <b>Days 1, 8 and 15</b>
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See LYMP DSG – Dose Banding document for more information		

**In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’**

## REQUIRED MONITORING

### Cycle 1 only

- Observe patient 1 hour post carfilzomib administration for Cycle 1 only (during Post hydration)
- Patient should be assessed for signs and symptoms of fluid overload prior to each carfilzomib dose

### All Cycles

#### Days 1 and 15

- CBC, reticulocyte count and biochemistry as per Physician Orders
- Physician should assess patient for signs and symptoms of cardiotoxicity prior to each cycle

## Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
valACYclovir	500 mg	Orally once daily

## DISCHARGE INSTRUCTIONS

- Reinforce oral hydration of 6 to 8 cups of liquid per day
- Remind patient to take dexamethasone at home
- Patients should be instructed to inform their cancer team of shortness of breath or signs and symptoms of fluid overload
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

## ADDITIONAL INFORMATION

- carfilzomib has been associated with cardiotoxicity